|
**Overview**: Spinocerebellar Ataxia 12 (SCA-12) Mutation Panel**Introduction**: The Spinocerebellar Ataxia 12 (SCA-12) Mutation Panel is a diagnostic tool designed to screen for SCA-12 using whole blood samples. In India, SCA-12 is one of the more common autosomal dominant cerebellar ataxias (prevalence ~1 in 10,000-20,000 in certain North Indian communities due to founder effect), caused by CAG repeat expansion in PPP2R2B gene (typically >46 repeats), presenting with action tremor, ataxia, and late-onset parkinsonism. High morbidity from underdiagnosis in rural/low-SES families with progressive gait instability or tremor, limited genetic labs, delayed supportive care or genetic counseling leading to falls, disability, or family recurrence. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for PPP2R2B gene mutation and CAG repeats over 1-2 days with high accuracy, valuable for confirming diagnosis and repeat sizing (correlates with age of onset/severity). This diagnostic falls under genetic disorder screening and targets patients with adult-onset tremor/ataxia or family history, addressing accurate detection to guide physical therapy, symptomatic management, and prenatal counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing disability burden in affected families. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: SCA-12 Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: SCA-12 CAG expansion identified 1999; in India, frequent in North Indian pedigrees.**Purpose**: The test assesses 2 parameters including PPP2R2B Gene Mutation to guide SCA-12 screening, confirm repeat expansion, inform prognosis/counseling.**Test Parameters**: 1. PPP2R2B Gene Mutation, 2. CAG Repeats.**Pretest Condition**: No fasting required; patients should have tremor/ataxia.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on tremor onset, family ataxia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed ataxia including progression, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CAG repeats (>46) confirm SCA-12, necessitating specialist input.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: MRI brain, family segregation analysis.**Test Limitations**: Repeat size interpretation complex; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Ataxia Studies India 2023. |
